RARE Daily

Aeglea Names Jeffrey Goldberg as CEO

December 1, 2022

Aeglea BioTherapeutics, which is developing enzyme therapeutics to treat rare metabolic diseases, named biotech veteran Jeffrey Goldberg as president, CEO, and board member.

Photo: Jeffrey Goldberg as president and CEO of Aeglea

Jim Kastenmayer will step down as interim chief executive officer and retain his position as Aeglea’s general counsel.

Goldberg is an accomplished biotech executive with more than 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and CEO of Immunitas Therapeutics. Prior to that, Goldberg served as the founding chief operating officer at Akcea where he was responsible for building functions and leading teams across all aspects of the business and eventually grew the team from two employees to more than 250 in multiple geographies. His past experience includes roles at the rare disease drug developer Proteostasis Therapeutics and Genzyme. He has an MBA and a MS in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.

“Jeff has successfully built and managed teams across a wide variety of functions, providing strong leadership and strategic direction. His breadth of experience spans from the founding of companies to overseeing successful global launches of rare disease therapies,” said Russell J. Cox, chair of the board of directors of Aeglea. “His proven ability to match business capabilities to unmet patient needs and then drive the strategy and execution needed to achieve those goals will be an important asset to Aeglea.”

Following the leadership transition and as part of the related evaluation of near-term corporate and clinical development strategy, Aeglea no longer plans to announce interim clinical data from the ongoing phase 1/2 clinical trial of pegtarviliase in classical homocystinuria in the fourth quarter of 2022.

The company is trading at around 42 cents, near a 52-week low. The company had a 52-week high of $6.26. It has a market cap of $25.8 million.

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.